Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Mainz Biomed BV (MYNZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: MYNZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.27% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.46M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 2 | Beta 0.3 | 52 Weeks Range 1.34 - 22.40 | Updated Date 07/4/2025 |
52 Weeks Range 1.34 - 22.40 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -22.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2307.21% |
Management Effectiveness
Return on Assets (TTM) -80.37% | Return on Equity (TTM) -465.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2452802 | Price to Sales(TTM) 6.1 |
Enterprise Value 2452802 | Price to Sales(TTM) 6.1 | ||
Enterprise Value to Revenue 2.74 | Enterprise Value to EBITDA -2.84 | Shares Outstanding 3814850 | Shares Floating 2706585 |
Shares Outstanding 3814850 | Shares Floating 2706585 | ||
Percent Insiders 1.95 | Percent Institutions 6.13 |
Upturn AI SWOT
Mainz Biomed BV
Company Overview
History and Background
Mainz Biomed BV, a molecular genetics diagnostics company based in Mainz, Germany, focuses on developing and commercializing innovative, accurate, and cost-effective early detection solutions for life-threatening diseases. Founded in 2007, it has evolved from a research-focused entity to a commercial-stage company with a growing portfolio of diagnostic tests.
Core Business Areas
- Colorectal Cancer Screening: Develops and commercializes diagnostic tests for the early detection of colorectal cancer (CRC). This includes ColoAlert, a highly sensitive and specific stool DNA test.
- Gastrointestinal Disease Diagnostics: Expands its portfolio to include tests for other gastrointestinal diseases to enhance diagnostic capabilities and patient care.
Leadership and Structure
The leadership team consists of experienced professionals in the fields of molecular diagnostics, biotechnology, and business development. The company's organizational structure includes departments dedicated to research and development, clinical affairs, regulatory affairs, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- ColoAlert: ColoAlert is a non-invasive stool DNA test for the early detection of colorectal cancer. It detects tumor DNA and is designed to be more convenient for patients than traditional colonoscopies. Market share is still emerging. Competitors include Exact Sciences' Cologuard (EXAS), and various fecal immunochemical tests (FIT). No current market share data available.
- PancarAlert: An early detection test for pancreatic cancer, which is in development. No current market share data available as it is not commercially available. Competitors would include imaging technologies and liquid biopsies.
Market Dynamics
Industry Overview
The molecular diagnostics market for cancer screening is growing due to increasing awareness of early detection benefits, technological advancements, and an aging population. The market is competitive, with established players and emerging companies vying for market share.
Positioning
Mainz Biomed BV is positioning itself as a leader in convenient and accurate early detection of CRC with ColoAlert. Its competitive advantage lies in its proprietary technology and commitment to patient-friendly diagnostic solutions.
Total Addressable Market (TAM)
The TAM for colorectal cancer screening is estimated to be in the billions of dollars globally. Mainz Biomed BV is aiming to capture a significant share of this market through the increased adoption of its ColoAlert test.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Non-invasive and patient-friendly tests
- Focus on early cancer detection
- Experienced leadership team
- Regulatory approvals in key markets
Weaknesses
- Limited commercial infrastructure compared to larger competitors
- Dependence on successful commercialization of ColoAlert
- Need for ongoing clinical validation of tests
- Relatively small market cap
Opportunities
- Expanding market for non-invasive cancer screening
- Potential partnerships with healthcare providers and insurance companies
- Geographic expansion into new markets
- Development of new diagnostic tests for other diseases
- Increasing awareness and acceptance of stool DNA testing
Threats
- Competition from established players with greater resources
- Changes in regulatory landscape
- Adverse clinical trial results
- Pricing pressures from insurance companies and healthcare providers
- Slow adoption of new diagnostic technologies
Competitors and Market Share
Key Competitors
- EXAS
Competitive Landscape
Mainz Biomed BV faces competition from established players such as Exact Sciences (EXAS) and other companies offering colonoscopy services and FIT tests. Mainz Biomed BV's competitive advantage lies in the non-invasive nature and convenience of its ColoAlert test, as well as its focus on early cancer detection. It needs to scale quickly to capture market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is driven by regulatory approvals, partnerships, and initial commercial traction for ColoAlert.
Future Projections: Future growth is projected to be significant, driven by increasing adoption of ColoAlert and the potential development and commercialization of PancarAlert. Analyst estimates vary but generally reflect optimism about the company's potential.
Recent Initiatives: Recent initiatives include expanding commercial operations in Europe, pursuing FDA approval for ColoAlert in the United States, and advancing the development of PancarAlert.
Summary
Mainz Biomed BV is an emerging growth company focused on early cancer detection. Its ColoAlert test is a promising non-invasive alternative to traditional colonoscopies. The company needs to scale its commercial operations and secure regulatory approvals to achieve its growth potential. It faces competition from larger, established players, and success depends on the wide adoption of its tests.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Mainz Biomed BV's Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and a thorough understanding of the company's financials and prospects.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mainz Biomed BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | CEO & Executive Director Mr. Guido Baechler | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 19 | Website https://mainzbiomed.com |
Full time employees 19 | Website https://mainzbiomed.com | ||
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.